

# DiaNat-DB: A Molecular Database of Antidiabetic Compounds from Medicinal Plants

Abraham Madariaga-Mazón,<sup>1,\*</sup> José J. Naveja,<sup>1</sup> José L. Medina-Franco,<sup>2</sup> Karla O. Noriega-Colima,<sup>1</sup> and Karina Martinez-Mayorga,<sup>1,\*</sup>


<sup>1</sup> Instituto de Química, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico ; naveja@comunidad.unam.mx (J.J.N.) ; k\_colima@hotmail.com (K.O.N.-C.)

<sup>2</sup> DIFACQUIM research group, Department of Pharmacy, School of Chemistry, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico; medinajl@unam.mx (J.L.M-F.)

\* Correspondence: amadariaga@iquimica.unam.mx (A.M.-M.); kmtzm@unam.mx (K.M.-M.); Tel.: +52 55 56224770 Ext 46614

















## Supplementary Information

|   |   |
|---|---|
| <b>Figure S1.</b> The taxonomic diversity and use of the most representative families in DiaNat-DB..... | 1 |
| <b>Table S1.</b> Exemplary DiaNat-DB compounds similar to antidiabetic drugs (DM-ref).....              | 2 |
| <b>Table S2.</b> Some of the most similar scaffolds between DiaNat-DB and FDA.....                      | 3 |
| <b>Table S3.</b> List of FDA-approved antidiabetic small molecules (DM-ref) from DrugBank.....          | 4 |

















**Figure S1.** The taxonomic diversity and use of the most representative families in DiaNat-DB.

**Table S1.** Exemplary DiaNat-DB compounds similar to antidiabetic drugs (DM-ref).

|                                    |   |   |   |  |  |  |
|------------------------------------|---|---|---|--|--|--|
| <p><b>Compound in DM-ref</b></p>   |  <p><u>Canagliflozin</u></p>               |   |   |  <p><u>Dapagliflozin:</u></p>               |  |  |
| <p><b>Similar in DiaNat-DB</b></p> |  <p>DiaNatDB-22<br/>Similarity: 0.80</p>   |  <p>DiaNatDB-290<br/>Similarity: 0.80</p>  |  <p>DiaNatDB-20<br/>Similarity: 0.79</p>    |  <p>DiaNatDB-18<br/>Similarity: 0.83</p>    |  <p>DiaNatDB-290<br/>Similarity: 0.80</p>   |  <p>DiaNatDB-22<br/>Similarity: 0.80</p>    |
| <p><b>Compound in DM-ref</b></p>   |  <p><u>Empagliflozin</u></p>               |   |   |  <p><u>Miglitol</u></p>                     |  |  |
| <p><b>Similar in DiaNat-DB</b></p> |  <p>DiaNatDB-18<br/>Similarity: 0.81</p> |  <p>DiaNatDB-22<br/>Similarity: 0.78</p> |  <p>DiaNatDB-290<br/>Similarity: 0.78</p> |  <p>DiaNatDB-120<br/>Similarity: 0.94</p> |  <p>DiaNatDB-221<br/>Similarity: 0.94</p> |  <p>DiaNatDB-222<br/>Similarity: 0.92</p> |

**Table S2.** Some of the most similar scaffolds between DiaNat-DB and FDA.

|                                     |  |  |   |
|-------------------------------------|--|--|---|
| <b>Scaffold in DiaNat-DB</b>        |   |    |    |
| <b>Most similar scaffold in FDA</b> | <br>Similarity: 0.75<br>Antidepressants, antihistaminic     |  <br>Similarity: 0.89<br>Progesterin medications, antidepressants.  | <br>Similarity: 0.86<br>Hyperhidrosis, stomach spasms  |
| <b>Scaffold in DiaNat-DB</b>        |   |    |    |
| <b>Most similar scaffold in FDA</b> | <br>FDA<br>Similarity: 1.0<br>Miglitol: <b>antidiabetic</b> |  <br>FDA<br>Similarity: 0.87<br>Progesterin medications, antidepressants, treatment of adrenogenital syndrome and adrenal insufficiency | <br>FDA<br>Similarity: 0.76<br>Analgesic, anti-inflammatory, <b>reduces risk of diabetic retinopathy</b> , Parkinson's disease |

**Table S3.** List of FDA-approved antidiabetic small molecules (DM-ref) from DrugBank.

| Drug                      | Mechanism of action / Target   |
|---------------------------|--|
| Acarbose                  | Alpha-glucosidase inhibitor that impairs digestion and absorption of carbohydrates in the small bowel. |
| Alogliptin                | Dipeptidyl peptidase 4 (DPP4) inhibitor.   |
| Canagliflozin             | Inhibitor of the kidney sodium-glucose transporter 2 (SGLT2).  |
| Clorpropamide             | Inhibitor of potassium ATP channel in pancreatic $\beta$ -cells (KATP).                                |
| Dapagliflozin             | SGLT2 inhibitor.   |
| Empagliflozin             | SGLT2 inhibitor.   |
| Ertugliflozin             | SGLT2 inhibitor.   |
| Glibenclamide / glyburide | KATP inhibitor.  |
| Gliclazide                | KATP inhibitor.  |
| Glimepiride               | KATP inhibitor.  |
| Glipizide                 | KATP inhibitor.  |
| Linagliptin               | DPP4 inhibitor.  |
| Metformin                 | AMPK activator (insulin sensitizer).   |
| Miglitol                  | Alpha glucosidase inhibitor.   |
| Nateglinide               | KATP inhibitor.  |
| Pioglitazone              | PPAR-gamma inhibitor (insulin sensitizer).   |

|               |                       |
|---------------|-----------------------|
| Repaglinide   | KATP inhibitor.       |
| Rosiglitazone | PPAR-gamma inhibitor. |
| Saxagliptin   | DPP4 inhibitor.       |
| Sitagliptin   | DPP4 inhibitor.       |
| Tolazamide    | KATP inhibitor.       |
| Tolbutamide   | KATP inhibitor.       |
| Vildagliptin  | DPP4 inhibitor.       |